Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI -1.49%45 Return-on-Tangible-Equity is 19.96% as of Dec. 2025, which is 20% below its 10-year median of 25.09. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 66.15% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:BKGI'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.52 Med: 25.09 Max: 109.83
Current: 8.6
During the past 7 years, Bangkok Genomics Innovation PCL's highest Return-on-Tangible-Equity was 109.83%. The lowest was 8.52%. And the median was 25.09%.
BKK:BKGI's Return-on-Tangible-Equity is ranked better than 66.15% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs BKK:BKGI: 8.60
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bangkok Genomics Innovation PCL Return-on-Tangible-Equity Related Terms
Bangkok Genomics Innovation PCL Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.96% mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Return-on-Tangible-Equity of 19.96% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 20% below median its historical median of 25.09. Over the past decade, Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity has ranged from 8.52 to 109.83. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #65 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 33.9%.
Is Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity too high?
Bangkok Genomics Innovation PCL's current Return-on-Tangible-Equity of 19.96% is 20% below median its 10-year median of 25.09. Over the past 10 years, this metric has ranged from a low of 8.52 to a high of 109.83. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #65 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #65 out of 192 companies for Return-on-Tangible-Equity. This puts Bangkok Genomics Innovation PCL in the upper half of its industry. Historically, Bangkok Genomics Innovation PCL's own Return-on-Tangible-Equity has ranged from 8.52 to 109.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Return-on-Tangible-Equity is 19.96%, which is 20% below median its own 10-year median of 25.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Return-on-Tangible-Equity of 19.96%. The current Return-on-Tangible-Equity is 19.96%, which is 20% below median its 10-year median of 25.09. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Return-on-Tangible-Equity is 19.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
